In deciding whether to pay for new medical technologies, the Centers for Medicare and Medicaid Services (CMS) is becoming more specific about its requirements for evidence of improved health outcomes.
In deciding whether to pay for new medical technologies, the Centers for Medicare and Medicaid Services (CMS) is becoming more specific about its requirements for evidence of improved health outcomes in the Medicare population. In our view, this is a positive and overdue step, but one whose rationale and likely consequences must be better understood by the medical community, policymakers, and the public. Expansions of access to health insurance under the health care reform legislation pending in Congress — and resulting financial pressures — would almost certainly intensify the emphasis on more relevant and robust evidence. link to original article
Help Improve This Site
Dr. Riviera, graduate of Club Med School, is studying the effects of having only four fingers and a bright yellow complexion has on patient outcomes.
His image is used temporarily, in good fun, and without permission.
FDA Issues Draft Guidance on "IRB Contiinuing Review After Clinical Investigation Approval" This guidance is much more comprehensive for IRBs, investigators and sponsors than the current guidance document on the subject matter of continuing review from FDA.
read more
Medicare and Medical Technology — The Growing Demand for Relevant Outcomes
Dr. Riviera, graduate of Club Med School, is studying the effects of having only four fingers and a bright yellow complexion has on patient outcomes.